Results 91 to 100 of about 1,844 (180)

Hypertrophic Cardiomyopathy in Athletes: A Paradigm Shift in Exercise Safety, the Role of Comorbid Factors, and the Impact of Anabolic Steroids - A Literature Review

Quality in Sport
    Hypertrophic cardiomyopathy (HCM) in athletes is a complex condition requiring individualized risk assessment and interdisciplinary management.
Martyna Jakubowska, Paulina Jakubowska, Mikołaj Szaryński, Julia Gólcz, Adam Sikorski, Adrian Gólcz, Karolina Kadłubowska, Jan Rytel, Natalia Chojnowska, Tomasz Bursztyn, Michał Bursztyn   +10 more
doaj   +1 more source

Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial [PDF]

, 2020
Abraham, T., Abraham, T. P., Afshar, K., Alvarez, P., Arad, M., Axthelm, C., Bach, R., Barriales-Villa, R., Bartunek, J., Becker, R., Bhattacharya, M., Bondue, A., Brunner-La Rocca, H. P., C. Y., Ho, Cardim, N., Charron, P., Choudhury, L., Dudek, D., Duengen, H. -D., Edelberg, J. M., Elliott, P., Fermin, D., Frey, N., Garcia Pavia, P., Garcia-Pavia, P., Gimeno Blanes, J., Gimeno-Blanes, J., Hagege, A., Halabi, M., Hegde, S. M., Hidalgo Urbano, R., Jacoby, D., Jefferies, J., Jensen, M., Jensen, M. K., Katz, A., Kramer, C., Kubanek, M., Lairez, O., Lakdawala, N., Lakdawala, N. K., Lester, S., Lester, S. J., Li, W., Marian, A., Masri, A., Maurer, M., Michels, M., Mitrovic, V., Mogensen, J., Monakier, D., Myers, J., Nagueh, S., Oko-Sarnowska, Z., Olivotto, I., Oreziak, A., Owens, A., Owens, D., Paz, O., Pereira, H., Preusch, M., Rader, F., Rincon Diaz, L. M., Saberi, S., Schulz-Menger, J., Sehnert, A. J., Seidler, T., Sherrid, M., Shirani, J., Solomon, S. D., Symanski, J., Thune, J. J., Trochu, J. -N., Turer, A., Van Craenenbroeck, E., Viskin, S., Waldman, C. B., Wang, A., Wever-Pinzon, O., Wheeler, M., Wheeler, M. T., Wojakowski, W., Wong, T., Yamani, M., Yousef, Z., Zemanek, D., Zhang, D., Zwas, D.   +87 more
core   +1 more source

A MECHANISTIC STUDY OF SARCOMERE LENGTH-DEPENDENT CALCIUM SENSITIVITY REGULATION OF CARDIAC MYOFILAMENTS [PDF]

Sarcomere length-dependent activation (sLDA) of cardiac filaments describes the maximum force performance and the calcium sensitivity, both of which increase with the sarcomere length during the diastolic state.
Wang, Xutu
core   +2 more sources

Mavacamten in real‐life practice: Initial experience at a hypertrophic cardiomyopathy centre

ESC Heart Failure
Aims In clinical trials, mavacamten reduced left ventricular outflow tract obstruction (LVOTO) and improved symptoms in patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
Zaid Abood, Muhammad Fuad Jan, Muddasir Ashraf, Stacie Kroboth, Heather Sanders, McKenzie Schweitzer, Amanda Misicka, Emily Ollerman, Arshad Jahangir, Patrycja Galazka, Abdul Jamil Tajik   +10 more
doaj   +1 more source

An ALPK3 truncation variant causing autosomal dominant hypertrophic cardiomyopathy is partially rescued by mavacamten [PDF]

The ALPK3 gene encodes alpha-protein kinase 3, a cardiac pseudo-kinase of unknown function. Heterozygous truncating variants (ALPK3tv) can cause dominant adult-onset hypertrophic cardiomyopathy (HCM).
Bagnall, Richard D., Beglov, Julia, Broadway-Stringer, Sophie, Davies, Benjamin, Douglas, Gillian, Fonseka, Oveena, Gehmlich, Katja, Hooper, Charlotte, Ingles, Jodie, Leinhos, Lisa, Lokman, Adam B., Nuthay, Sajjad, Ormondroyd, Elizabeth, Poloni, Giulia, Redwood, Charles, Robinson, Paul, Schmid, Manuel, Semsarian, Christopher, Singer, Evie, Thomson, Kate, Toepfer, Christopher N., Watkins, Hugh   +21 more
core   +2 more sources

Impact of Mavacamten on Force Generation in Single Myofibrils from Rabbit Psoas and Human Cardiac Muscle [PDF]

, 2020
Coppini, Raffaele, Dente, Marica, Ferrantini, Cecilia, Piroddi, Nicoletta, Poggesi, Corrado, Scellini, Beatrice, Tesi, Chiara   +6 more
core   +1 more source

Mavacamten maintenance dose determination: insights into individualised therapy for hypertrophic cardiomyopathy

Open Heart
Aims Mavacamten, the first approved myosin inhibitor for symptomatic obstructive hypertrophic cardiomyopathy (oHCM), addresses hypercontractility and left ventricular outflow tract (LVOT) obstruction.
Kawa Mohemed, Smita Scholtz, Volker Rudolph, Jan-Christian Reil, Max Potratz, Cédric Coppée, Vasco Sequeira, Werner Scholtz   +7 more
doaj   +1 more source

Dystrophic cardiomyopathy: the role of myofilaments [PDF]

Dystrophic cardiomyopathy is the consequence of diseases that affect the protein dystrophin. Dystrophin forms part of the dystrophin glycoprotein complex and is postulated to act as a membrane stabilizer, protecting the sarcolemma from contractioninduced
George, Thomas G.
core   +1 more source

Mavacamten in Hypertrophic Cardiomyopathy: Unraveling Therapeutic Potential and Clinical Implications in Advancing Cardiovascular Medicine [PDF]

Hypertrophic cardiomyopathy (HCM) is a genetic disorder characterized by myocardial hypertrophy, often leading to various cardiovascular symptoms and complications.
Ankit Kumar, Prachi Pandey, Dilip Jangid, Sanjeevani Tyagi, Rahul Raj
core   +1 more source

Exploring contractile protein mechanisms and target medications for cardiomyopathic patients with diastolic dysfunction

Pediatric Discovery
Genetic defects have been increasingly found in cardiomyopathies, which are often present with mutations in cardiac contractile proteins. These congenital defects involve numerous intracellular pathways and share several critical clinical features, such ...
Dustin Gerber, Junjun Quan, Bo Pan, Xupei Huang, Jie Tian   +4 more
doaj   +1 more source